D1400147 + D14000136 + D14000137 + Epanova®
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relative Bioavailability
Conditions
Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Trial Timeline
Feb 12, 2015 → Jul 27, 2015
NCT ID
NCT02359045About D1400147 + D14000136 + D14000137 + Epanova®
D1400147 + D14000136 + D14000137 + Epanova® is a phase 1 stage product being developed by AstraZeneca for Relative Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT02359045. Target conditions include Relative Bioavailability, AUC, Cmax.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02359045 | Phase 1 | Completed |
Competing Products
6 competing products in Relative Bioavailability
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab + Sonelokimab | MoonLake Immunotherapeutics | Phase 1 | 28 |
| ABT-333 | AbbVie | Phase 1 | 33 |
| BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg | AstraZeneca | Phase 1 | 33 |
| Ropivacaine 0.1% + Ropivacaine 0.4% | Baxter | Approved | 82 |
| Sulfatinib T capsule + Sulfatinib R capsule | HUTCHMED | Phase 1 | 28 |
| Tebipenem tablet form | Spero Therapeutics | Phase 1 | 25 |